Aug 2026· Molecular and Cellular Biochemistry· 0 citations· 49 references
Medicine
TL;DR
The therapeutic potency of Lomitapide was established to target Hippo pathway through disrupting ROCK activity in EMT dynamics, evident by upregulation of epithelial markers and downregulation of mesenchymal markers, through western blotting, qRT-PCR and immunofluorescence studies.
BACKGROUND
Lung adenocarcinoma (LUAD) is a leading cause of cancer-related mortality, characterized by aggressive progression and therapy resistance. Ferroptosis, an iron-dependent form of regulated cell death, has emerged as a promising therapeutic avenue. However, the role of Ribonucleotide Reductase M2 (RRM2) in fer...
Xiangyuan Li, Fenfen Gu, R. Xiao et al.· Pathology, Research and Prac...· 0 citations
It is demonstrated that activation of β-catenin is associated with a poor prognosis in melanoma and inhibiting the enzymatic activity of MICAL2 offers a promising and innovative strategy to improve outcomes in β-catenin-driven melanoma.
P. Sohier, J. Raymond, Zackie Aktary et al.· Cell Death and Differentiati...· 0 citations
It is demonstrated that Fraxetin exerts multi-faceted effects against colorectal cancer, including anti-cancer activity, synergy with chemotherapy, and restoration of 5-FU sensitivity in 5-FU-resistant CRC cells in vitro, through multi-target inhibition of the PI3K-Akt signaling pathway.
Min-Fang Guo, Liang-Dong Zhu, Jian-Jin Guo et al.· Biochemical and Biophysical...· 0 citations
BUB1 was significantly upregulated in UCEC tumors compared with normal endometrium, associated with advanced disease stage and reduced overall survival, confirming its role as an unfavorable prognostic biomarker and therapeutic target in UCEC.
Wajahat Ali, M. A. Al Mamun, Yi-Cheng He et al.· Future Journal of Pharmaceut...· 0 citations
These findings demonstrate that EZH2 inhibition promotes coordinated epigenetic remodeling and disrupts key oncogenic pathways in breast cancer cells, and suggest potential combinatorial strategies integrating EZH2 inhibition with other targeted or epigenetic therapies to enhance treatment efficacy, overcome resistance...
Thaís Amanda Damasceno Silva, E. V. Fernandes, Mayara Bocchi et al.· Clinical Breast Cancer· 0 citations
TAK1 is established as a key hub in cisplatin resistance and 5Z7 reverses resistance by targeting TAK1 to coordinately regulate NF-κB/p53 signaling, providing a foundation for potential clinical translation.
Wenyan Lu, Kunhao Tang, Zechen Wang et al.· Biochemical Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
